Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PROGESTATIONAL HORMONES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 487 records · Page 27Linked to original sources
PubMed1975

The synthesis of prostaglandin F by human endometrium in organ culture.

Slices of human endometrium obtained from hysterectomy specimens were cultured for 48 hours in an organ culture medium supplemented with ethanol (control, vehicle), 17-beta-estradiol (.5 mug/ml), or progesterone (.5 mug/ml). Uncultured endometrial tissue, cultured tissues, and the media were assayed for prostaglandin F (PGF) by a radioimmunoassay technique. Hematoxylin and eosin and periodic acid-Schiff stain histologic controls were done on all tissues. The concentrations of PGF in picograms/milligram, corrected for percent recovery, in the differently treated tissues were: preculture 298; culture control 2210; estrogen-treated 2680; progesterone-treated 1260. All differences except those between estrogen and control (p greater than .10) and progesterone and control (p less than .10) are significant at the p = .02 level or better. Progesterone appears to inhibit PGF synthesis which occurs during in vitro culture of human endometrium; estrogen tended to increase PGF synthesis in this system.

Adult↗
PubMed1978

Termination of early pregnancy by a single-dose 3.0 mg 15-methyl PGF2alpha methyl ester vaginal suppository.

The abortifacient effect of a single-dose, long-acting vaginal suppository containing 3.0 mg of 15-methyl PGF2 alpha methyl ester was investigated in 104 early pregnancies. The pregnancy was terminated in 91 per cent of the cases. The abortion was uncomplicated in 79 patients, while 12 patients experienced prolonged bleeding. In 21 uncomplicated cases, VabraR curettage done 4 weeks after therapy revealed necrotic residual tissue in 16 patients and nonspecific endometritis in 20 patients. Residual tissue was found in about 50 per cent of the patients curettaged after 1st menstruation, but no residua was found after 2nd menstruation. In patients with prolonged bleeding, substantial amounts of necrotic residual tissue was found in all patients curettaged 4 weeks after therapy. The decline of serum hCg and plasma progesterone levels was significantly slower in these patients as compared with uneventful abortions.

Abortifacient Agents↗
PubMed1983

Evaluation of a rapid method for determination of total urinary estrogens in morning samples from normally menstruating women.

Total urinary estrogens (TUE) in morning urine samples delivered during seven days around midcycle from 14 normally menstruating women were analyzed and the results were compared with those obtained by radioimmunoassay of serum estradiol-17 beta (E2) and LH. The Spinnbarkeit of the cervical mucus was also determined daily and ovulation was confirmed by RIA of serum progesterone. Significant correlations (p less than 0.01) between day of peak levels of serum E2 and the day with the highest TUE value were obtained. Peak values for Spinnbarkeit, estradiol, TUE and LH were on the average obtained on cycle day 13.1 (10-17), 13.3 (10-16), 13.9 (11-18) and 14.1 (11-17), respectively, and the mean cycle length was 27.9 (24-32) days. The difference in mean peak day for estradiol and TUE, estradiol and Spinnbarkeit, estradiol and LH was significant in each comparison (p less than 0.01). Assays of TUE in morning samples as compared to analysis of TUE in 24 h urine portions were compared during 48 h in 10 women. The day with the highest TUE excretion was found to be the same in 7 women irrespective of the type of urinary sample analyzed. Analysis of urinary creatinine did not improve the TUE results. Levels of TUE in normally cycling females (n = 14); in women taking contraceptive steroids (n = 10), in menopausal women (n = 10) and in normal men (n = 10) agreed with those previously reported. It is concluded that the TUE determination by RIA may be helpful as a rapid method for everyday clinical use.

Adult↗
PubMed1986

Suppression of ovarian function by Microgynon 30 in day 1 and day 5 "starters".

The suppression of ovulation during the first treatment cycle with Microgynon 30 (150 micrograms levonorgestrel and 30 micrograms ethinyl oestradiol) for nine subjects starting the "pill" on day 1 of their cycle and five subjects on day 5 was investigated. Serum oestradiol and progesterone levels throughout the cycle and midcycle urinary LH levels were reliably suppressed in all day 1 "starters". Serum progesterone levels and urinary LH levels were also suppressed in day 5 "starters" but one subject produced oestradiol levels within the normal range of ovulatory cycles. Mean oestradiol levels of day 5 "starters" were found to be significantly higher than those of day 1 "starters" (p less than 0.05).

Adolescent↗
PubMed1979

A new long-acting injectable microcapsule system for the administration of progesterone.

A long-acting injectable microcapsule system for the controlled-release systemic administration of progesterone (P4) is described. The system consists of microcapsules made of the biodegradable polymer, d,l-polylactic acid, which contain crystalline P4. Following injection, P4 is released from the microcapsules by diffusion and biodegradation of the polymer matrix. The rate of P4 release from the prototype microcapsule system in vivo is 1.3 microgram of P4/day/mg of microcapsules, and the duration of release is 30 days. Vaginal estrous cycles in rats and cyclic ovarian function in baboons were inhibited for 1 month following a single injection of P4 microcapsules. The effects of continuous progesterone therapy on reproductive function in both rats and baboons are dose-dependent. The utility of the system as a once-a-month injectable contraceptive is established in the baboon model.

Animals↗
PubMed1980

Differences in hormonal patterns during the first postabortion menstrual cycle after two techniques of termination of pregnancy.

Fifteen patients underwent first-trimester abortion by one of two techniques. In group P, seven patients received prostaglandin vaginal suppositories during the 12 hours prior to vacuum aspiration, whereas eight patients in group V were aborted by aspiration alone. During the first postabortion menstrual cycle, daily peripheral blood levels of several hormones, including follicle-stimulating hormone (FSH), luteinizing hormone, human chorionic gonadotropin, estradiol, and progesterone, were determined. Patients in group P demonstrated a more rapid fall in progesterone levels following pregnancy termination (P less than 0.01). They also experienced a more physiologic first postabortion cycle as evidenced by a larger preovulatory estradiol peak (P less than 0.05) and a more normal luteal phase as judged by both the duration and elevation of progesterone levels. Certain endocrine changes common to both groups but different from those of normally menstruating women were also observed. These consisted of short-term spurts of progesterone secretion in many patients (10 of 15) prior to ovulation and exaggerated levels of FSH during the early follicular phase.

20-alpha-Dihydroprogesterone↗
PubMed1988

The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.

Seventeen healthy women aged 24-45 years with regular menstrual periods, proven fertility and not using steroidal contraceptives or IUD were recruited for the study. The volunteers were followed during one control, one treatment and one follow-up cycle. Daily morning urine samples were obtained during the control and the treatment cycle. The samples were analysed with regard to pregnanediol glucuronide (P2-G), oestrone glucuronide (E1-G), oestradiol (E2), progesterone (P4), LH and creatinine. During the entire 3-month study the subjects kept a record of uterine bleeding and side effects. The subjects received 50 mg RU486 daily either on cycle days 7-10 (n = 7) or on cycle days 20-23 (n = 10). An endometrial biopsy was taken on cycle day 10 in the first group and on cycle days 21-28 in the second group of patients. Treatment during the proliferative phase caused significant prolongation of the cycle length due to a delay of the oestrogen and LH surge. However, once the oestrogen concentration started to increase, the remaining part of the cycle was normal. The length of the follow-up cycle was similar to that of the control cycle. The morphology of the endometrium did not differ from control samples taken from untreated women at the same time of the cycle. All ovulating women (n = 9) treated in the mid-luteal phase started to bleed on the 3rd to 4th day of the treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1980

Cytosol oestradiol and progesterone receptors in endometrial hyperplasia and adenocarcinoma: determination by single saturating dose exchange assays.

Available oestradiol and progesterone binding site concentrations in endometrial cytosols were determined by simplified single saturating dose assay in 16 normal women with proliferative endometrium, in 10 patients with endometrial hyperplasia, and in 20 patients with endometrial adenocarcinoma. The mean oestrogen receptor level tended to be higher in endometrial hyperplasia than in either proliferative or carcinomatous endometria. Mean progesterone receptor levels were comparable in proliferative and hyperplastic endometria, but were sequentially lower in highly differentiated carcinoma, moderately differentiated carcinoma, and undifferentiated carcinoma. Correlation between results obtained by single saturating dose assays and by conventional Scatchard analysis in those endometria subjected to both procedures was high for both oestrogen (r = 0.998) and progesterone (r = 0.949) and indicates that with the simplified assays, large scale clinical studies on hormone sensitivity of endometrial adenocarcinomas are feasible.

Adenocarcinoma↗